{"url_path":"/sec/lpcn/8-k/2026-09-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-042286-index.html","accession_number":"0001493152-26-042286","cik":"0001535955","ticker":"LPCN","issuer_name":"Lipocine Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-042286-index.html","primary_entity_key":"0001535955","primary_entity_name":"Lipocine Inc."},"word_count":114,"has_tables":true,"body_markdown":"**Item\n8.01. Other Events.**\n\n \n\nOn\nSeptember 8, 2026, Lipocine Inc. (the “Company”) and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed\nthat the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales\nAgent (the “Sales Agreement”) will be up to 3.0%, subject to adjustment by the Company and the Sales Agent.\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nSeptember 11, 2026\nLIPOCINE\nINC.\n\n \n \n\n \nBy:\n*/s/\nMahesh V. Patel*\n\n \nName:\n\nMahesh\nV. Patel\n\n \nTitle: \nPresident\nand Chief Executive Officer"}